Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study

References

• Subbiah A, Subbiah G. Diabetes research in India and China today: From literature-based mapping to health-care policy. Current Science 2002;82(9):1086-97
   Web of Science ®Google Scholar
• Li G, Hu Y, Pan X. Prevalence and incidence of NIDDM in Daqing City. Chin Med J (Engl) 1996;109:599-02
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective study. BMJ 2000;321(7258):405-12
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo XH, Vaz JA; PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diabetes Obes Metab 2009;11:33-40
   PubMed Web of Science ®Google Scholar
• Garber A, Wahlen J, Wahl T, et al.; for the 1-2-3 study group. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2009;8(1):58-66
   Google Scholar
• Yang WY, Ji QH, Zhu DL, et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008;31:852-6
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al. The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008;62:1809-19
   PubMed Web of Science ®Google Scholar
• Yang WY, Benroubi M, Borzi V, et al. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Curr Med Res Opin 2009;2:2643-54
   Google Scholar
• World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 1 May 1996
   Google Scholar
• Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006;15(3):481-91
   PubMed Web of Science ®Google Scholar
• Barry JG. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003;4(Suppl. 6):S3-S10
   Google Scholar
• Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in noninsulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Med 1998;15:297-303
   PubMed Web of Science ®Google Scholar
• Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care JT – Diabetes Care 1997;20(11):1664-9
   PubMedGoogle Scholar
• Baum L, Ng MC, So WY, et al. Effect of hepatic lipase -514C->T polymorphism and its interactions with apolipoprotein C3 -482C->T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in Chinese type 2 diabetic patients. Diabetes Care JT – Diabetes care 2005;28(7):1704-9
   PubMed Web of Science ®Google Scholar
• Yang X, So WY, Kong AP, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care JT – Diabetes Care 2007;30(1):65-70
   PubMed Web of Science ®Google Scholar
• Chen L, Lei L, Jin T, et al. Plasma metallothionein antibody, urinary cadmium, and renal dysfunction in a Chinese type 2 diabetic population. Diabetes Care JT – Diabetes Care 2006;29(12):2682-7
   PubMed Web of Science ®Google Scholar
• Douek IF, Allen SE, Ewings P, et al.; for the Metformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22(5):634-40
   PubMed Web of Science ®Google Scholar
• Goudswaard AN, Furlong NJ, Rutten GE, et al.Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004;4:CD003418
   Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65(3):385-411
   PubMed Web of Science ®Google Scholar